Ivosidenib after stem cell transplant for IDH1-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML with an IDH1 mutation, detected anytime in the past.
- You are between 18 and 75 years old.
- You are planning to receive a stem cell transplant from a donor.
- Your kidneys, liver, and heart are working well enough (for example, your heart pumps at least 40% of blood per beat).
- You have not had a prior stem cell transplant for AML.
- Your cancer is not growing or returning right now, and you have no active serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
This trial tests whether taking ivosidenib after a stem cell transplant can help prevent leukemia from coming back in people with a specific gene change called IDH1. It may be an option if you have AML or MDS with that mutation and are recovering from transplant.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Hear when a new IDH1 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.